Mariusz Rosołowski

Dr. Mariusz Rosołowski

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Gastroenterology Review
Verified
Journal Article
Open access
MRMariusz Rosołowski
Mariusz Rosołowski
MKMaciej Kierzkiewicz
Maciej Kierzkiewicz
Infectious esophagitis may be caused by fungal, viral, bacterial or even parasitic agents. Risk factors include antibiotics and steroids use, chemotherapy and/or radiation therapy, malignancies and immunodeficiency syndromes including acquired immunodeficiency syndrome. Acute onset of symptoms...

24 December 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
NSNatalia Sroka
Natalia Sroka
ARAlicja Rydzewska-Rosołowska
Alicja Rydzewska-Rosołowska
KKKatarzyna Kakareko
Katarzyna Kakareko
MRMariusz Rosołowski
Mariusz Rosołowski
IGIrena Glowinska
Irena Glowinska
Tomasz HryszkoTomasz Hryszko
Tomasz Hryszko
The microbiota, as a complex of microorganisms in a particular ecosystem, is part of the wider term—microbiome, which is defined as the set of all genetic content in the microbial community. Imbalanced gut microbiota has a great impact on the homeostasis of the organism. Dysbiosis, as a disturbance in bacterial balance, might trigger or exacerbate the course of different pathologies. Small intestinal bacterial overgrowth (SIBO) is a disorder characterized by differences in quantity, quality, and location of the small intestine microbiota. SIBO underlies symptoms associated with functional gastrointestinal disorders (FGD) as well as may alter the presentation of chronic diseases such as heart failure, diabetes, etc. In recent years there has been growing interest in the influence of SIBO and its impact on the whole human body as well as individual systems. Therefore, we aimed to investigate the co-existence of SIBO with different medical conditions. The PubMed database was searched up to July 2022 and we found 580 original studies; inclusion and exclusion criteria let us identify 112 eligible articles, which are quoted in this paper. The present SIBO diagnostic methods could be divided into two groups—invasive, the gold standard—small intestine aspirate culture, and non-invasive, breath tests (BT). Over the years scientists have explored SIBO and its associations with other diseases. Its role has been confirmed not only in gastroenterology but also in cardiology, endocrinology, neurology, rheumatology, and nephrology. Antibiotic therapy could reduce SIBO occurrence resulting not only in the relief of FGD symptoms but also manifestations of comorbid diseases. Although more research is needed, the link between SIBO and other diseases is an important pathway for scientists to follow.

11 December 2020 in Toxins
Verified
Journal Article
Open access
PDF file
ARAlicja Rydzewska-Rosołowska
Alicja Rydzewska-Rosołowska
NSNatalia Sroka
Natalia Sroka
KKKatarzyna Kakareko
Katarzyna Kakareko
MRMariusz Rosołowski
Mariusz Rosołowski
EZEdyta Zbroch
Edyta Zbroch
Tomasz HryszkoTomasz Hryszko
Tomasz Hryszko
The last years have brought an abundance of data on the existence of a gut-kidney axis and the importance of microbiome in kidney injury. Data on kidney-gut crosstalk suggest the possibility that microbiota alter renal inflammation; we therefore aimed to answer questions about the role of microbiome and gut-derived toxins in acute kidney injury. PubMed and Cochrane Library were searched from inception to October 10, 2020 for relevant studies with an additional search performed on ClinicalTrials.gov. We identified 33 eligible articles and one ongoing trial (21 original studies and 12 reviews/commentaries), which were included in this systematic review. Experimental studies prove the existence of a kidney-gut axis, focusing on the role of gut-derived uremic toxins and providing concepts that modification of the microbiota composition may result in better AKI outcomes. Small interventional studies in animal models and in humans show promising results, therefore, microbiome-targeted therapy for AKI treatment might be a promising possibility.

1 January 2014 in Gastroenterology Review
Verified
Journal Article
Closed access
MRMariusz Rosołowski
Mariusz Rosołowski
MHMarek Hartleb
Marek Hartleb
TMTomasz Marek
Tomasz Marek
JMJanusz Milewski
Janusz Milewski
KLKrzysztof Linke
Krzysztof Linke
GRGrażyna Rydzewska
Grażyna Rydzewska
Gastroesophageal varices are one of the most serious consequences of portal hypertension. One-third of patients with varices will develop variceal haemorrhage. Despite significant improvements in the outcomes of treatment, mortality due to bleeding from gastro-oesophageal varices still remains...

1 January 2018 in Gastroenterology Review
Verified
Journal Article
Open access
PDF file
RKRoland Kadaj-Lipka
Roland Kadaj-Lipka
MLMichał Lipiński
Michał Lipiński
KAKrystian Adrych
Krystian Adrych
MDMarek Durlik
Marek Durlik
AGAnita Gąsiorowska
Anita Gąsiorowska
GRGrażyna Rydzewska
Grażyna Rydzewska
This article describes the latest diagnostic and therapeutic recommendations in chronic pancreatitis, developed by the Working Group of the Polish Society of Gastroenterology and the Polish Pancreas Club. The recommendations refer to the diagnosis of chronic pancreatitis, autoimmune pancreatitis,...

1 January 2016 in Gastroenterology Review
Verified
Journal Article
Open access
MRMariusz Rosołowski
Mariusz Rosołowski
MLMichał Lipiński
Michał Lipiński
MDMarek Dobosz
Marek Dobosz
MDMarek Durlik
Marek Durlik
SGStanislaw Gluszek
Stanislaw Gluszek
GRGrazyna Rydzewska
Grazyna Rydzewska
The presented recommendations concern the current management of acute pancreatitis. The recommendations relate to the diagnostics and treatment of early and late phases of acute pancreatitis and complications of the disease taking into consideration surgical and endoscopic methods. All the...